SEC Form 3 · accession 0001209191-17-026725
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas E Darcy
Officer — Executive Vice President · Director
Period of report
Apr 12, 2017
Accepted (ET)
Apr 12, 2017 · 6:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 369,565 | I | By Thomas Eric Darcy and Janet E. Darcy, Trustees of the Darcy Family Trust dated September 21, 2001 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.94 | holding | — | — | — | — | Mar 13, 2023 | Common Stock | 66,666 | — | D |
| Employee Stock Option (right to buy)F2 | $14.98 | holding | — | — | — | — | Jun 9, 2026 | Common Stock | 16,666 | — | D |
Explanation of responses
- F1The stock option is fully vested.
- F21/4th of the shares vest one year after 4/1/2016; 1/48th of the shares vest monthly thereafter over the next 3 years.